Trial reportBMJ (Clinical research ed.)2010
Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
Trial report in BMJ (Clinical research ed.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Journal of lower genital tract disease · 2012Pooled it
- Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review.BMJ (Clinical research ed.) · 2011Pooled it
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.CA: a cancer journal for cliniciansGuideline
- Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.BMJ open · 2017Trial
- Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.British journal of cancer · 2012Trial
- Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Trial
- Clinical relevance of partial HPV genotyping in cervical cancer screening.Scientific reports · 2026Article
- A novel non-invasive mRNA-lncRNA biomarker panel for accurate prediction of cervical squamous cell carcinoma and adenocarcinoma.Journal of gynecologic oncology · 2025Article
- Divergent effects of switching from cytology to HPV-based screening in the Nordic countries.European journal of public health · 2024Article
- Cervical precancerous and cancerous lesions screening using Pap smear test at Provincial Referral Hospital of Bukavu, Eastern DR Congo: profile and recommendations to stakeholders.The Pan African medical journal · 2024Article
- Analysis of the cervical microbiome in women from the German national cervical cancer screening program.Journal of cancer research and clinical oncology · 2023Article
- Incorporating HPV 33 and cytology into HPV 16/18 screening may be feasible. A cross-sectional study.Archives of gynecology and obstetrics · 2023Article
- The Future of Cervical Cancer Prevention: From "One-Size-Fits-All" to Personalized Screening.Journal of personalized medicine · 2023Article
- Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.Viruses · 2018Review
- HPV self-sampling: A promising approach to reduce cervical cancer screening disparities in Canada.Current oncology (Toronto, Ont.) · 2018Article
- Incidence Trends of Cervical Cancer and Its Precancerous Lesions in Women of Central Switzerland from 2000 until 2014.Frontiers in medicine · 2018Article
- Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.Journal of general internal medicine · 2016Article
- [Screening for cervical and breast cancer].Der Pathologe · 2016Review
- Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval.BMC public health · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the performance and impact of primary human papillomavirus (HPV) DNA screening with cytology triage compared with conventional cytology on cervical cancer and severe pre-cancerous lesions.
designRandomised trial.
settingPopulation based screening programme for cervical cancer in southern Finland in 2003-5.
participants58 076 women, aged 30-60, invited to the routine population based screening programme for cervical cancer.
interventionsPrimary HPV DNA test (hybrid capture II) with cytology triage if the result was positive or conventional cytological screening (reference).
main outcome measuresRate of cervical cancer, cervical intraepithelial neoplasia (CIN) grade III, and adenocarcinoma in situ (as a composite outcome referred to as CIN III+) during 2003-7 through record linkage between files from the screening registry and the national cancer registry.
resultsIn the HPV and conventional arms there were 95 600 and 95 700 woman years of follow-up and 76 and 53 cases of CIN III+, respectively (of which six and eight were cervical cancers). The relative rate of CIN III+ in the HPV arm versus the conventional arm was 1.44 (95% confidence interval 1.01 to 2.05) among all women invited for screening and 1.77 (1.16 to 2.74) among those who attended. Among women with a normal or negative test result, the relative rate of subsequent CIN III+ was 0.28 (0.04 to 1.17). The rate of cervical cancer between arms was 0.75 (0.25 to 2.16) among women invited for screening and 1.98 (0.52 to 9.38) among those who attended.
conclusionsWhen incorporated into a well established organised screening programme, primary HPV screening with cytology triage was more sensitive than conventional cytology in detecting CIN III+ lesions. The number of cases of cervical cancer was small, but considering the high probability of progression of CIN III the findings are of importance regarding cancer prevention.
trial registrationCurrent Controlled Trials ISRCTN23885553.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.